Navigation Links
Spanish gene expression data promise targeting of anti-angiogenesis treatment
Date:4/29/2010

Analyzing the expression of particular genes in lung cancers could soon allow researchers to identify groups of patients who are likely to benefit most from treatment with angiogenesis-inhibitor drugs, a Spanish team reports.

Dr Eloisa Jantus from the General University Hospital of Valencia reports new findings from an analysis of 135 lung cancer specimens. She and her colleagues, led by Dr Carlos Camps, evaluated the expression of 8 different genes related to vascular endothelial growth factor (VEGF), a molecule that helps tumors develop the blood supply they need to grow larger. VEGF is a key target for new "anti-angiogenesis" drugs that aim to arrest this process.

"The vascular endothelial growth factor (VEGF) family of ligands and receptors has an important role in tumor angiogenesis," Dr Jantus said. "We studied the expression, at molecular level, of the members of this family in tumor samples as well as in normal lung tissues in order to understand their role in tumor development and prognosis."

The group measured the expression of the 8 genes, including VEGF A, -B, -C and PIGF, tyrosine-kinase receptors VEGFR-1, VEGFR-2 and VEGFR-3. In addition to these receptors, they also studied related genes for neuropilins NRP1 and NRP2.

The researchers then correlated gene expression levels with important clinical outcomes, including overall survival and the time to tumor progression, in patients whose tumors were surgically removed.

"Patients whose tumors expressed high levels of VEGF-A and VEGFR-1 tended to have a worse prognosis in terms of progression-free survival and overall survival," Dr Jantus said. "The subgroup of patients with high levels of expression of VEGF-A and VEGFR-1 showed a 30% shorter time to progression and overall survival, when compared to those with low expression levels."

The findings provide early clues that 'angiogenic profiles' could define subgroups of patients who will better benefit from the use of anti-angiogenic therapies, the researchers say.

"We think that it seems improbable that a single angiogenic marker will provide all of the relevant clinical information because only one biomarker cannot reflect the complexity of the angiogenic process; however, when the markers were considered in combination, they provided a more comprehensive pattern or profile, significantly improving their prognostic value."

These angiogenic profiles need validation in larger groups of patients before they can be implemented in the clinic, the researchers note, however they represent an emerging way to improve lung cancer therapy by tailoring it to the characteristics of individual patients and their tumors.


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. LifeLinks Revolutionizes Video Interpreting, Shows Spanish Interpreting in Added Dimension-VIDEO!
2. Prescriptions Translated to Spanish Could Be Hazardous to Health
3. HealthLinkRx Announces Classes in Spanish for Occupational and Physical Therapists
4. Yakult USA Launches Spanish-Language Website
5. Put Some Fiesta Into Dinner - Sam's Club Adds New Spanish Red Wine From Torres Winery
6. ECELA Spanish School in Argentina Offers Students Opportunity to Work in Buenos Aires Free Health Fair
7. Spanish Only, Please: Special Latino Clinic Launched For Potential Abdominal Transplant Patients
8. Spanish-Speaking Mothers Less Likely to Turn on TV
9. Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books
10. Gene expression test reduces need for invasive heart muscle biopsy
11. Personal Tragedy Reveals Untapped Artistic Expression / Family Business Memorializes Loved Ones with Compassion During Grieving
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... In the United States alone, up to 36% of primary ... of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known ... effective treatment options, the San Diego Gamma Knife Center offers a precision-medicine ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered ... feedback from high school and college students who have participated in the program every ... and YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to ...
(Date:3/29/2017)... Burnaby, BC (PRWEB) , ... March 29, 2017 ... ... smile makeover services with or without a referral to new patients from Burnaby, ... implants or other full mouth reconstruction services, can see the esteemed team ...
(Date:3/29/2017)... ... March 29, 2017 , ... How ... other outpatient facilities, and who are the most active developers? , In ... and Healthcare Real Estate Insights (HREI) found that outpatient medical real estate development ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Zynex (OTCQB: ZYXI), an innovative ... of non-invasive medical devices for pain management, stroke rehabilitation, ... will host the Company,s 2016 full-year investor webcast on Monday, ... The Company expects to file its 2016 ... ...
(Date:3/29/2017)... , March 29, 2017 According to a new ... Type (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, ... 2021" published by MarketsandMarkets, the market is expected to reach USD 1,215.4 ... of 6.5% from 2016 to 2021. Continue ... ...
(Date:3/29/2017)... WASHINGTON , March 29, 2017  The Pharmaceutical ... regarding a new PhRMA report on patient out-of-pocket spending: ... for Medicare and Medicaid Services (CMS), the average amount ... be 13% of drug spending in 2016, down from ... is a pricing problem, not a coverage problem. Health ...
Breaking Medicine Technology: